Study of MHB088C for Patients With Advanced Solid Malignant Tumors
ConditionAdvanced/Metastatic Solid Tumors
Trial statusRecruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorQilu Pharmaceutical Co., Ltd.
About this trial
This is a Phase I/II, multicenter, open-label clinical trial with dose escalation/dose expansion/efficacy expansion phases, designed to evaluate the safety/tolerability, pharmacokinetics, immunogenicity and preliminary efficacy of MHB088C in participants with advanced solid tumors
Eligibility criteria
Qualifiers
Agree to follow the experimental treatment plan and visit plan, join the group voluntarily, and sign a written informed consent form;
Age ≥ 18 years old when signing the informed consent form;
The Eastern Cooperative Oncology Group's physical status scoring standard (ECOG) is 0~1;
The expected survival time is at least 3 months;
Disqualifiers
Has more than 2 primary malignancies before signing of Informed Consent Form.
Has received anti-tumor treatment before the first dose of investigational product; Medication of traditional Chinese medicine before the first dose of investigational drug.
Medication of other unmarketed investigational drugs or therapies before the first dose of investigational drug.
Presence of unstable brain metastases and/or leptomeningeal carcinomatosis.
Trial design
Treatments tested in this trial
- MHB088C for Injection
Treatment groups
515 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov